



Press release – February 7, 2019

## DMS Group and Hybrigenics enter into exclusive negotiation

**Diagnostic Medical Systems Group (Euronext Paris - FR0012202497 - DGM)** and **Hybrigenics (Euronext Growth - FR0004153930 - ALHYG)** today announces entering into exclusive negotiation for a takeover of Hybrigenics by DMS Group through the transfer of its DMS Biotech division dedicated to biotechnology.

DMS Biotech is in charge of the development strategy of DMS Group in the field of biotechnology, and especially research based on the injection of adipose stem cells for the treatment of arthrosis and in regenerative medicine. DMS Biotech is composed of the Stemcis company (fully-owned by DMS Group) and of its Adip'Sculpt subsidiary, which sells devices and equipment for lipofilling, an adipose tissue autografting technique used in plastic and reconstructive surgery.

The necessary due diligences, checks and appropriate analyses will start to determine the best conditions in which this operation could be structured to be proposed for potential approval to the shareholders.

At this stage, subject to the outcome of the due diligences and on the basis of a provisional exchange ratio which will need to be confirmed by a "Commissaire aux apports", the parity provisionally set by the parties would be 82% DMS Biotech and 18% Hybrigenics. The conclusion of this operation would therefore be conditioned by the exemption to the obligation to file a public offer, to be granted by the "Autorité des marchés financiers".

The final detailed conditions of the proposed operation will be published at a later date in a subsequent press release.

